Oncology

Analysis shows that the therapy is associated with a reduced acute toxicity burden associated with intensity-modulated radiation therapy.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Ponatinib (Iclusig; Takeda) combined with reduced-intensity chemotherapy achieved higher minimal residual disease-negative complete remission rates in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia compared to imatinib.

Sugar…may not always be sweet. Survivors of childhood cancer have a risk of accelerated aging with every 25 grams of sugar consumed, according to researchers.

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

GDA-501, a novel, genetically modified, nicotinamide natural killer pre-clinical cell therapy.

Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

Under specific circumstances and criteria, they are adjustable to approximate OS in selected populations of Canadian patients who have advanced non–small cell lung cancer.

FDA approves brentuximab vedotin for the treatment of patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

Study shows there are 2.5 times more breast cancer survivors since the last estimate was conducted in 2007.

A physician working in the field of palliative care discusses how pharmacists and physicians can work together to help address issues pertaining to polypharmacy through deprescribing.

Improvement is seen with a higher suspicion of disease and extended timelines, analysis demonstrates.

Research indicates that administering vitamin C to dendritic cells produces more consistent activation of genes involved in the immune response.

Efficacy results comparing the cemiplimab-rwlc combination to chemotherapy alone showed a 22-month median overall survival versus 13 months.

Study shows combining brentuximab vedotin with the standard chemotherapy regimen reduced the risk of relapse in children with high-risk Hodgkin lymphoma by 10%.

A session presenter at the ASCP 2022 Annual Meeting addresses research investigating the value of preventative treatments when patients have a limited life expectancy.

Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody.

Promising data suggest triplet regimens may more effectively treat patients with unresected and metastatic intrahepatic cholangiocarcinoma.

It may be worth considering the pathophysiology and vascular complications of chemotherapy, especially among patients who are already hypertensive.

UC Davis cancer researchers hope new technology will help diagnose and treat melanoma more successfully.

In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.

Study finds little evidence to support the long-standing recommendation that women with a first-degree family relative diagnosed with breast cancer should get screened 10 years earlier.

Pharmacy Times will be covering the American Society of Nephrology (ASN) Kidney Week, which will be gathering more than 10,000 professionals working on kidney health in Orlando, Florida.

Epcoritamab is an investigational subcutaneous bispecific antibody being investigated for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

A compound often found in citrus fruits, nobiletin, could be a less toxic and more effective treatment for cholangiocarcinoma.

Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.

Inflammation-based prognostic scores can be a valuable tool in assessing the overall survival of patients with intrahepatic cholangiocarcinoma.